| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director, 10% Owner
1 company
Jason Lettmann is Chief Executive Officer at ALXO. Jason Lettmann's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $380K at current prices.
Historically, Jason Lettmann's trades have earned a strong insider score of 74/100 across 10 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +9.4%.
Net of sales, the ALXO filings show accumulation of 6,537 shares.
Jason Lettmann has 23 Form 4 filings on record from July 2020 to August 2026, all as Chief Executive Officer at ALX Oncology (ALXO), 2020–2026.
The 57 reported transactions were 32 open-market sales, 11 option or other derivative awards, 5 open-market purchases and 5 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $7.7M and 6 sales worth about $13.6M.
The largest open-market purchase was 400,000 shares of ALXO at an average $19.00 on July 21, 2020, about $7.6M.
The largest open-market sale was 325,377 shares of ALXO at an average $27.36 on December 13, 2021, about $8.9M. Twelve months later ALXO was down 51%.
None of the 4 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | ALXO Alx Oncology Holdings Inc. | Chief Executive Officer | Sell | 2,230 | $1.93 | $4,303.90 | -0.8% | - | - | |
| Mar 19, 2026 | ALXO Alx Oncology Holdings Inc. | Chief Executive Officer | Sell | 12,311 | $2.17 | $26,714.87 | -4.0% | -33.8% | - | |
| Sep 17, 2025 | ALXO Alx Oncology Holdings Inc | Chief Executive Officer | Buy | 92,233 | $1.08 | $99,352.24 | +43.3% | +36.2% | +65.7% | |
| Aug 15, 2025 | ALXO Alx Oncology Holdings Inc | Chief Executive Officer | Sell | 2,382 | $0.64 | $1,525.43 | -1.1% | +89.4% | +204.2% | |
| Feb 19, 2025 | ALXO Alx Oncology Holdings Inc | Chief Executive Officer | Sell | 2,159 | $1.15 | $2,483.28 | -1.3% | -64.0% | +118.5% | |
| Mar 14, 2024 | ALXO Alx Oncology Holdings Inc | Chief Executive Officer | Buy | 4,400 | $11.31 | $49,771.48 | +2.6% | -23.5% | -92.6% | |
| Dec 13, 2021 | ALXO Alx Oncology Holdings Inc | Director, 10% Owner | Sell | 325,377 | $27.36 | $8,901,803.95 | -53.2% | -33.0% | -51.4% | |
| Dec 10, 2021 | ALXO Alx Oncology Holdings Inc | Director, 10% Owner | Sell | 145,637 | $32.26 | $4,698,091.14 | -33.3% | -39.9% | -65.4% | |
| Jul 21, 2020 | ALXO Alx Oncology Holdings Inc | Director, 10% Owner | Buy | 400,000 | $19.00 | $7,600,000.00 | -105.8% | - | - |